Pimozide
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Pimozide: From Tourette Syndrome to Trichotillomania
One-Sentence Summary
Pimozide is a diphenylbutylpiperidine-class antipsychotic historically used as a backup treatment for Gilles de la Tourette syndrome and other psychotic disorders. The TxGNN model predicts it may be effective for Trichotillomania (compulsive hair-pulling disorder), with 0 clinical trials and 10 publications currently supporting this direction, largely from small open-label and case-level experience.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Tourette Syndrome (per international literature; no Taiwan/India license data available) |
| Predicted New Indication | Trichotillomania |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DG002, DrugBank query pending). Based on available literature, Pimozide is a diphenylbutylpiperidine-class antipsychotic acting as a central dopamine D2 receptor antagonist; this mechanism underlies its established efficacy in Tourette syndrome and other dopamine-mediated conditions.
Trichotillomania is increasingly conceptualized as part of an obsessive-compulsive/impulse-control spectrum, with striatal dopamine–serotonin interaction dysregulation proposed as a contributing pathophysiology. Because low-dose typical neuroleptics (including pimozide) have shown benefit as augmentation agents in SSRI-refractory obsessive-compulsive-spectrum conditions, a mechanistic rationale exists for exploring pimozide as an SSRI-augmentation strategy in trichotillomania.
The supporting evidence, however, is limited to one small open-label case series (PMID 1532960, n small, augmentation design) plus narrative reviews and case reports discussing pimozide’s broader use in dermatology/psychodermatology. No randomized controlled trials or registered clinical trials currently exist for this specific indication, and pimozide carries a well-known QT-prolongation risk that must be weighed against any potential benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36802832 | 2023 | Review (RCT evidence mapping) | J Cutan Med Surg | Systematic evidence mapping of RCTs for pharmacological treatment of primary psychodermatologic disorders |
| 1532960 | 1992 | Cohort (open-label) | J Clin Psychiatry | Low-dose pimozide augmentation of SSRIs showed benefit in trichotillomania, based on phenomenological overlap with Tourette syndrome/OCD |
| 10900563 | 2000 | Cohort | Int J Psychiatry Med | Clinical profile of delusional parasitosis (related psychodermatologic/monosymptomatic hypochondriacal spectrum) |
| 15554735 | 2004 | Review | Am J Clin Dermatol | Comprehensive review of pimozide in dermatologic practice, noting efficacy in monosymptomatic hypochondriacal psychosis |
| 30446201 | 2018 | Review | Clin Dermatol | Overview of antipsychotic drugs (including pimozide) in dermatology via D2/H1/muscarinic/α1 receptor effects |
| 27320510 | 2016 | Review | Tijdschr Psychiatr | Treatment options for pediatric trichotillomania; notes limited pharmacotherapy research |
| 11475941 | 2001 | Review | CNS Drugs | Clinical features and treatment approaches for psychogenic excoriation, a related impulse-control condition |
| 10497682 | 1999 | Review | Ann Acad Med Singap | Overview of trichotillomania as an under-diagnosed psychiatric syndrome |
| 28225970 | 2017 | Case Report | An Bras Dermatol | Case report of trichotillomania with dermatoscopic differential diagnosis vs. alopecia areata |
| 10357517 | 1999 | Case Report | J Child Adolesc Psychopharmacol | Three cases of risperidone addition following prior open-label pimozide benefit in SRI-refractory trichotillomania |
India Market Information
Pimozide is currently not marketed in India/Taiwan (0 registrations on file); no license or product registration data is available to tabulate.
Safety Considerations
- Drug Interactions: 247 total interactions on file (source: DDInter). Notable Major-level interactions include Hydrocortisone, Amphotericin B (and lipid complex), Bupropion, Aprepitant, Morphine, Lorcaserin, Cimetidine, Potassium citrate, Clarithromycin, Picosulfuric acid, and Polyethylene glycol (3350 with electrolytes). Moderate-level interactions include Famotidine, Epinephrine, Hyoscyamine, Loperamide, Atropine, Bisacodyl, Glycopyrronium, and Dicyclomine.
Key warnings and contraindications from the official product label are not yet available (blocking data gap — TFDA label has not been retrieved); please refer to the package insert once available for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to L3 (a single small open-label augmentation case series plus reviews/case reports, no RCTs or registered trials), and the drug is not currently marketed in Taiwan/India. A blocking data gap on official label warnings/contraindications (DG001) prevents a full S1 safety evaluation, particularly given pimozide’s known QT-prolongation liability.
To proceed, the following is needed:
- TFDA/official product label with warnings, contraindications, and QT-prolongation guidance (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- A dedicated ECG/QT monitoring protocol if clinical exploration proceeds
- Assessment of market registration pathway in India/Taiwan, since the drug currently has zero local licenses
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.